KRAS and medical procedure: Inhibition of in vivo tumor growth by Ab3‐8 was not observed in HT29 colon and HeLa uterus cancer cells with wild‐type KRAS. These results suggest that ASCT2 is an excellent therapeutic target for KRAS‐mutated cancers.